title: Low-dose tenofovir is more potent than adefovir and is effective in controlling HBV viremia in chronic HBeAg-negative hepatitis B.
abstract: OBJECTIVE
  To study the efficacy of tenofovir disoproxil fumarate (TDF) at low dose in a small open trial of chronic hepatitis B patients with advanced stage disease.
  
  
  METHODS
  Eleven patients were treated with TDF 75 mg for a median period of 80 (range, 24-576) wk and then 7 cases were shifted to an adefovir 10 mg treatment group. All patients had been pre-treated with lamivudine: 5 had YMDD resistant mutants and 6 wild-type virus. When TDF was started, 4 patients had low-level viremia and 6 were PCR-negative.
  
  
  RESULTS
  During TDF treatment, PCR remained negative in 10 patients, transaminase levels were normal and no significant viral breakthrough was observed. The drug was well tolerated in all cases. When TDF 75 mg was substituted with adefovir 10 mg, 3 out of 7 patients had a persistent viral rebound (2700-130,000 copies/mL), in whom lamivudine had to be reintroduced.
  
  
  CONCLUSIONS
  Low-dose TDF monotherapy can control HBV viremia for an extended period of time without the emergence of resistance and is more potent than adefovir at the standard dosage. The use of a reduced dose of TDF could diminish the cost of therapy in low-income countries, but further studies in a larger population and in HBeAg-positive subjects are needed.
authors: Hepatology Unit, Treviglio Hospital, Piazza Ospedale 1, 24047 Treviglio (Bg), Italy. pdpoggio@ospedale.treviglio.bg.it
authors: Paolo
authors: P
authors: Del Poggio
authors: Maurizio
authors: M
authors: Zaccanelli
authors: Maria
authors: M
authors: Oggionni
authors: Silvia
authors: S
authors: Colombo
authors: Carlo
authors: C
authors: Jamoletti
authors: Vesna
authors: V
authors: Puhalo
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D024882:Drug Resistance, Viral; D005260:Female; D006509:Hepatitis B / Q000188:drug therapy* / Q000276:immunology*; D006513:Hepatitis B e Antigens / Q000378:metabolism*; D006515:Hepatitis B virus / Q000187:drug effects / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000627:therapeutic use*; D000068698:Tenofovir; D014766:Viremia / Q000188:drug therapy* / Q000276:immunology
chemical_list: D000998:Antiviral Agents; D006513:Hepatitis B e Antigens; D063065:Organophosphonates; C053001:adefovir; D000068698:Tenofovir; D000225:Adenine
references: Ann Intern Med. 2005 May 17;142(10 ):821-31
references: 15897532
references: Hepatology. 2007 Feb;45(2):507-39
references: 17256718
references: Hepatology. 2006 Aug;44(2):318-25
references: 16871563
references: Clin Infect Dis. 2006 Oct 1;43(7):904-10
references: 16941375
references: Hepatology. 2005 Jul;42(1):239-40
references: 15962310
references: Clin Pharmacokinet. 2004;43(9):595-612
references: 15217303
references: J Acquir Immune Defic Syndr. 2005 Aug 1;39(4):406-11
references: 16010161
references: Hepatology. 2006 Aug;44(2):309-13
references: 16871562
references: HIV Med. 2005 Jul;6(4):284-90
references: 16011534
references: Ann Intern Med. 2003 Sep 2;139(5 Pt 1):313-20
references: 12965939
references: Antivir Ther. 2005;10(6):727-34
references: 16218172
references: Hepatology. 2004 Dec;40(6):1421-5
references: 15565615
references: Hepatology. 2005 Jun;41(6):1391-8
references: 15915463
references: Antimicrob Agents Chemother. 2006 Jul;50(7):2471-7
references: 16801428
references: Health Technol Assess. 2006 Aug;10 (28):iii-iv, xi-xiv, 1-183
references: 16904047
references: World J Gastroenterol. 2006 Jul 14;12(26):4203-5
references: 16830375
references: J Viral Hepat. 2002 Jan;9(1):52-61
references: 11851903
references: J Viral Hepat. 2005 Jul;12(4):364-72
references: 15985006
references: Natl Med J India. 2002 Nov-Dec;15(6):320-7
references: 12540064
references: Int J Antimicrob Agents. 2007 May;29(5):510-7
references: 17346940
references: JAMA. 2004 Jul 14;292(2):191-201
references: 15249568
references: Int J Clin Pract. 2004 Sep;58(9):877-86
references: 15529522